Holen Sie sich die Stockscreener-App
549.57
0.66%
3.61
Handel nachbörslich:
549.57
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$545.96
Offen:
$545.96
24-Stunden-Volumen:
332.93K
Relative Volume:
0.69
Marktkapitalisierung:
$23.33B
Einnahmen:
$3.17B
Nettoeinkommen (Verlust:
$1.29B
KGV:
20.28
EPS:
27.0947
Netto-Cashflow:
$1.01B
1W Leistung:
+0.90%
1M Leistung:
-3.34%
6M Leistung:
+9.85%
1J Leistung:
+93.95%
1-Tages-Spanne:
$538.71
$554.09
1-Wochen-Bereich:
$536.39
$557.97
52-Wochen-Spanne:
$272.12
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
549.57 | 23.17B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.31B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 40.32B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Underweight |
| 2025-09-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
United Therapeutics CFO Edgemond sells $5.49m in company stock By Investing.com - Investing.com Nigeria
United Therapeutics CFO Edgemond sells $5.49m in company stock - Investing.com
Neuroblastoma Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Y-mAbs Therapeutics, United Therapeutics Corp, EUSA Pharma, Clarity Pharma, Eli Lilly - Barchart.com
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.2m in stock - Investing.com
iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns - The Motley Fool
United Therapeutics CEO Rothblatt sells $5.2m in shares By Investing.com - Investing.com Canada
United Therapeutics CEO Rothblatt sells $5.2m in shares - Investing.com
United Therapeutics CFO James Edgemond sells $5.48m in stock - Investing.com
United Therapeutics CFO James Edgemond sells $5.48m in stock By Investing.com - Investing.com Australia
Goodwin Advises Ascidian Therapeutics On A Global Research Collaboration With Eli Lilly For Up To $1.9 Billion - Mondaq
Martine Rothblatt, United Therapeutics CEO, sells $5.2m in stock By Investing.com - Investing.com South Africa
Martine Rothblatt, United Therapeutics CEO, sells $5.2m in stock - Investing.com
United Therapeutics Corporation (UTHR) Stock Analysis: Investor Outlook on Robust Growth Potential with 20.98% Upside - DirectorsTalk Interviews
United Therapeutics CEO Rothblatt sells $5.47m in stock - Investing.com
UTHRUnited Therapeutics Corp Stock Price and Quote - Finviz
Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report? - Yahoo Finance
How The Story Around United Therapeutics (UTHR) Is Shifting On Trials Pricing And Valuation - Yahoo Finance
MannKind develops inhaled ralinepag formulation for United Therapeutics - Investing.com
United Therapeutics EVP Mahon sells $4.54 million in stock - Investing.com UK
United Therapeutics Q1 2026 slides: IPF breakthrough offsets revenue miss - Investing.com
MannKind stock surges on United Therapeutics partnership deal - Investing.com
United Therapeutics EVP Mahon sells $4.54 million in stock By Investing.com - Investing.com Australia
United Therapeutics stock hits all-time high at 608.87 USD - Investing.com
UTHR Technical Analysis & Stock Price Forecast - Intellectia AI
UTHR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Tectonic Therapeutic Stock Climbs as Broader Market Sinks - Bez Kabli
Xenotransplantation Explained: How Animal Organs Could Transform Medicine - News-Medical
Acute Respiratory Distress Syndrome Market to Grow - One News Page
Rothblatt (United Therapeutics) sells $5.3m in UTHR stock - Investing.com
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study - The Manila Times
United Therapeutics CFO James Edgemond sells $5.48m in shares - Investing.com UK
United Therapeutics CEO Rothblatt sells $863,947 in stock By Investing.com - Investing.com Nigeria
United Therapeutics CEO Martine Rothblatt sells $5.2m in company stock - Investing.com Nigeria
United Therapeutics CFO James Edgemond sells $5.48m in shares By Investing.com - Investing.com India
United Therapeutics CEO Rothblatt sells $863,947 in stock - Investing.com
United Therapeutics CEO Martine Rothblatt sells $5.2m in company stock By Investing.com - Investing.com South Africa
Vanguard (VHT) Vs. Simplify (PINK): Which Healthcare ETF Is the Better Buy for Investors? - The Motley Fool
Simplify Health Care ETF (PINK) vs. Vanguard Health Care ETF (VHT): A Detailed ComparisonNews and Statistics - IndexBox
Liquidia Sinks 5% After Recent Rally - Bez Kabli
United Therapeutics Corporation (UTHR) Stock Analysis: Exploring a 19.47% Potential Upside - DirectorsTalk Interviews
United Therapeutics Corporation (UTHR): Renaissance Technologies Likes This Biotech Stock - Insider Monkey
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):